Search PubMed⌕ Search

Biomedical subjects

G Meco

Publications and source records attributed to G Meco.

At least 91 records · Page 5Linked to original sources
PubMed1984

Naloxone-induced jumping activity in morphine-dependent mice: a pharmacological study on the role of DA2 receptors.

The morphine withdrawal syndrome is strictly related to modifications on neurotransmittorial systems at central and peripheral levels. Dopamine seems to play an important role. Particularly in the experimental withdrawal syndrome the jumping activity seems to be related to a hypersensitivity of DA receptors. While the role of DA1 receptors has been extensively studied, using agonist and antagonist drugs, the role of DA2 receptors is still little known. In our study we evaluated the changes of the jumping response that was induced by substances active on DA2 receptors (lisuride, tiapride) in mice made acutely dependent on morphine, in which we induced a withdrawal syndrome with naloxone. Haloperidol (DA1-DA2 blocker) did not provoke significant changes. Either tiapride or lisuride determined a sharp increase of jumping.

Animals↗
PubMed1984

A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.

Preliminary open trials performed by the authors and others with Moclobemide, a new MAO-A inhibitor, indicated that the drug has a satisfactory antidepressant activity. In the present double-blind study Moclobemide has been compared to placebo in a group of 34 unipolar psychotic or neurotic depressed patients. The mean daily dose of Moclobemide was 297 mg and treatment lasted from two to four weeks. Drug effectiveness was measured by improvements in the Hamilton Rating Scale for Depression (HRSD), Clinical Global Impression (CGI) and 100 mm Visual Analogue Scale (VAS). The results have shown that the active drug was markedly superior to placebo. The mean total score of HRSD was reduced from 41.7 to 16.5 in 18 pts. treated with Moclobemide and from 36.3 to 29.1 in 16 pts. who received placebo. Self-assessment with VAS showed a mean reduction from 82.7 mm to 42.2 mm and from 84.3 to 70.6 mm respectively. Moderate to marked improvement was observed by the CGI in 15 cases treated with Moclobemide and mild to moderate in 5 cases who received placebo. The treatment was well tolerated.

Adult↗
PubMed1984

Changed plasma prolactin levels after etoperidone and placebo.

A neuroendocrinological study was carried out by evaluating plasma prolactin levels after etoperidone i.m. (100 mg) and placebo. Fourteen male inpatients (mean age: 35.36 +/- 11.7 years) with chronic schizophrenia were selected for the study, whose aim was to improve interpretation of the pharmacological activity of etoperidone. The results suggest that etoperidone plays the role of an atypical psychotropic drug since it does not affect prolactin levels. In addition, the drug is devoid of anticholinergic effects, which facilitates its prospective clinical use for medium-term and long-term therapy.

Adolescent↗
PubMed1983

Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.

The effects of Rolipram, a new phosphodiesterase inhibitor, were assessed in a double-blind trial versus placebo in 10 patients with Parkinson's disease already under treatment. Contrary to previous findings with specific phosphodiesterase inhibitors, with Rolipram (at the dose of 3 mg per day), no significant deterioration of the therapeutic action of dopamine agonist Lisuride was noted.

3',5'-Cyclic-AMP Phosphodiesterases↗
PubMed1982

Phospholipid liposomes in depression: a double-blind study versus placebo.

Phospholipid liposomes (PL) are capable of stimulating the activity of dopamine (DA)-sensitive adenylate cyclase in mouse brain, and inducing a modification of the noradrenergic hypothalamic system in rat. Changes of prolactin and growth hormone secretion have been observed in humans given PL. A recent double-blind clinical study suggests that liposomes have a good antidepressive effect in depressive patients. 26 patients with depressive syndrome were included in a double-blind study; 13 patients were treated with clomipramine (CI) + placebo (P), and 13 with CI + PL. The dose of CI was 75 mg orally daily, that of PL was 200 mg by intravenous infusion in 500 ml isotonic saline solution daily. The symptomatology was evaluated on days 0, 7, 14, and 21 using the Hamilton Rating Scale. The results of this controlled trial have shown that both treatment were effective on overall symptomatology but the onset of action of CI + PL was more rapid than CI + P.

Adult↗
PubMed1982

Pyridoxine and depression: neuroendocrine aspects.

Plasma prolactin levels (PRL) were determined in 5 male depressed patients and in 5 controls, after injection of TRH (200 mg i.v.) (first phase), TRH following oral L-DOPA (500 mg) given 90 minutes before (second phase), TRH plus pyridoxine (300 mg i.v.) after same pretreatment with L-Dopa (third phase). L-Dopa induced a statistically significant suppression of TRH, caused PRL release; such suppression appears to be lower when TRH plus pyridoxine were administered simultaneously. PRL profile was not significantly different in the two groups.

Depressive Disorder↗